BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024)
BioLineRx (BLRX) posted quarterly Current Deferred Revenue of $2.3 million for Q3 2024, down 58.83% quarter-over-quarter from $5.5 million in Q2 2024.
Powered by 
Analysis
BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024) Analysis & Trends
BioLineRx's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $2.3 million for Q3 2024.
- In Q3 2024, Current Deferred Revenue changed N/A year-over-year to $2.3 million; the TTM figure through Sep 2024 stood at $2.3 million (changed N/A YoY), while the FY2023 annual figure was $13.0 million, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2024 stood at $2.3 million, down from $5.5 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $13.0 million in Q4 2023, with the low at $2.3 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | BioLineRx | 6.64 Bn | 6.64 Bn | 235,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 5.48 Mn |
| Mar 31, 2024 | 9.03 Mn |
| Dec 31, 2023 | 12.96 Mn |